Epis NexLab

Epis NexLab is a South Korean biotechnology company established in 2025 as a wholly-owned subsidiary of Samsung Epis Holdings. The company is dedicated to the development of next-generation biotechnology platforms, with a primary focus on transforming highly scalable peptide-related technologies into drug discovery engines. By leveraging its core platform, Epis NexLab aims to rapidly generate and develop diverse new drug candidates across multiple therapeutic areas, including oncology and immunology. The company operates under a biotech business model, prioritizing open innovation and seeking strategic partnerships or licensing agreements with global pharmaceutical firms. Epis NexLab represents a strategic pivot for the Samsung group into novel drug development beyond its established biosimilar business.